# US 2026/0232636 A1 · Inhibitors of lrrk2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232636 A1
- Document ID: US20260232636A1
- Status: Published application
- Kind: A1
- Application number: 19/153,251
- Filed: 2024-03-01
- Published: 2026-08-13
- Earliest claimed: 2023-03-01
- Assignees: Vanderbilt University
- Applicants: Vanderbilt University
- Inventors: Craig W. Lindsley; Changho Han; Upendra Rathnayake; Joseph D. Bungard; Hyekyung Kelly Plumley
- Web page: https://patentgrep.com/patent/US20260232636A1

## CPC

- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 31/433: Thidiazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 31/08: for leprosy
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Indazole- and azaindazole-substituted octahydrocyclopenta[c]pyrrole and hexahydrocyclopenta[c]pyrrole compounds are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
“” represents a single bond or a double bond;
R1 is
R1a is G1, -L1-G1, —C2-4alkylene-ORA, —C2-4alkylene-NRARB, C1-6alkyl, C1-6fluoroalkyl, or H;
RA is G1, -L1-G1, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, or —C1-3alkylene-C3-6cycloalkyl;
RB is H, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, or —C1-3alkylene-C3-6cycloalkyl;
R1b is halogen, C1-4alkyl, C1-2fluoroalkyl, CN, C3-4cycloalkyl, —OC1-3alkyl, —OC1-2fluoroalkyl, or H;
R1c is H, halogen, C1-4alkyl, C1-2fluoroalkyl, CN, phenyl, C3-4cycloalkyl, —OR1d, or —N(R1d)2;
R1d, at each occurrence, is independently H, C1-4alkyl, C1-2fluoroalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl, wherein alternatively two R1d, together with a nitrogen to which the two R1d attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
L1 is C1-5alkylene or C2-5alkenylene;
G1 is a 5- to 6-membered aromatic or partially unsaturated heterocyclic ring containing a first nitrogen and optionally 1-2 additional heteroatoms that are independently nitrogen, oxygen, or sulfur, the heterocyclic ring being attached at an unsaturated carbon in the heterocyclic ring or G1 is phenyl, G1 being optionally substituted with a first substituent selected from the group consisting of halogen, C1-4alkyl, cyano, C1-2fluoroalkyl, oxo, —OR10, —N(R10)2, —C1-3alkylene-OR10, C3-5cycloalkyl, and —C1-3alkylene-C3-5cycloalkyl, and optionally further substituted with 1-2 substituents independently selected from the group consisting of halogen, C1-4alkyl, cyano, and C1-2fluoroalkyl;
R10, at each occurrence, is independently H, C1-4alkyl, C1-2fluoroalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl, wherein alternatively two R10, together with a nitrogen to which the two R10 attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
R2 is G2, -L2-G2, -L3-C1-6alkyl, —C2-6alkylene-R2a, C1-6alkyl, C1-6fluoroalkyl, or H;
L2 is C1-3alkylene or L3;
L3 is C(O), SO2, S(O)(NH), C(O)NH, or C(O)O;
G2 is a 4- to 12-membered heterocyclyl, a C3-12carbocyclyl, a 5- to 12-membered heteroaryl, or a 6- to 12-membered aryl, wherein G2 is optionally substituted with a first substituent selected from the group consisting of halogen, cyano, C1-4alkyl, C1-2fluoroalkyl, G2a, oxo, —OR13, —N(R13)2, —C1-3alkylene-OR13, —C1-3alkylene-N(R13)2, —C(O)N(R13)2, —C(O)OR13, —SO2R13 and S(O)(NH)R13, optionally further substituted with oxo, and optionally further substituted with 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-4alkyl, and C1-2fluoroalkyl;
G2a is a C3-4cycloalkyl;
R13, at each occurrence, is independently H, C1-4alkyl, C1-2fluoroalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl, wherein alternatively two R13, together with a nitrogen to which the two R13 attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
R2a is —OR14, —N(R14)2, —SO2R14, S(O)(NH)R14, —NR14C(O)N(R14)2, or —NR14C(O)OR14;
R14, at each occurrence, is independently H, C1-4alkyl, C1-2fluoroalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl, wherein alternatively two R14, together with a nitrogen to which the two R14 attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
R3, at each occurrence, is independently fluoro or C1-4alkyl; and
n is 0, 1, or 2.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1a is G1; and G1 is the optionally substituted 5- to 6-membered aromatic heterocyclic ring.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring system of the optionally substituted 5- to 6-membered aromatic heterocyclic ring at G1 contains 1-2 nitrogens.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G1 is optionally substituted with a first substituent selected from the group consisting of halogen, C1-4alkyl, cyano, C1-2fluoroalkyl, —OR10, C3-5cycloalkyl, and —C1-3alkylene-C3-5cycloalkyl, and further optionally substituted with 1-2 substituents independently selected from the group consisting of halogen and C1-4alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1a is G1; and G1 is the optionally substituted 5- to 6-membered partially unsaturated heterocyclic ring.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring system of the optionally substituted 5- to 6-membered partially unsaturated heterocyclic ring is 1,2-dihydropyridin-4-yl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G1 is

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1b is halogen or C1-4alkyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1c is H.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is G2 or -L2-G2.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L2 is C1-3alkylene, or wherein L2 is L3 and L3 is C(O).

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G2 is the optionally substituted 4- to 12-membered heterocyclyl or the optionally substituted C3-12carbocyclyl.

### Claim 15 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein the ring system of the optionally substituted 4- to 12-membered heterocyclyl at G2 is a 4- to 8-membered heterocyclyl or an 8- to 10-membered fused bicyclic heterocyclyl, the heterocyclyls containing 1-2 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein the ring system of the optionally substituted C3-12carbocyclyl at G2 is a C3-6cycloalkyl.

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G2 is the optionally substituted 5- to 12-membered heteroaryl or the optionally substituted 6- to 12-membered aryl.

### Claim 19 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein the ring system of the optionally substituted 5- to 12-membered heteroaryl at G2 is a 5- to 6-membered heteroaryl containing 1-3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G2 is

### Claim 22 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0.

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 24 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has formula (II-C) or formula (III-C):

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The compound of claim 1 selected from the group consisting of:
6-((3aR,6aS)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5-yl)-5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazole;
tert-butyl (3aR,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,6aS)-2-(tetrahydro-2H-pyran-4-yl)-1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
4-((3aR,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(1H)-yl)tetrahydro-2H-thiopyran 1,1-dioxide;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5s,6aS)-2-(tetrahydro-2H-pyran-4-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5r,6aS)-2-(tetrahydro-2H-pyran-4-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
4-((3aR,5s,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)tetrahydro-2H-thiopyran 1,1-dioxide;
4-((3aR,5r,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)tetrahydro-2H-thiopyran 1,1-dioxide;
(4-methyl-1,2,3-thiadiazol-5-yl)((3aR,5s,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methanone;
(4-methyl-1,2,3-thiadiazol-5-yl)((3aR,5r,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methanone;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5s,6aS)-2-(tetrahydro-2H-pyran-3-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5r,6aS)-2-(tetrahydro-2H-pyran-3-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5s,6aS)-2-(tetrahydrofuran-3-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5r,6aS)-2-(tetrahydrofuran-3-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
3-((3aR,5s,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)tetrahydro-2H-thiopyran 1,1-dioxide;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5s,6aS)-2-(oxetan-3-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-((3aR,5r,6aS)-2-(oxetan-3-yl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-indazole;
methyl 3-((3aR,5s,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)piperidine-1-carboxylate;
methyl 3-((3aR,5r,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)piperidine-1-carboxylate;
3-((3aR,5r,6aS)-5-(5-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)tetrahydro-2H-thiopyran 1,1-dioxide;
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 1)

A method of treating a disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is a CNS disease or disorder, an immunological disease or disorder, a cancer, or leprosy.

### Claim 29 (depends on 28)

The method of claim 28, wherein the disease or disorder is:
a CNS disease or disorder and the CNS disease or disorder is selected from the group consisting of familial/genetic and/or sporadic Parkinson's disease, a tauopathy, Alzheimer's disease, neuroinflammation, HIV-induced dementia, ALS, ischemic stroke, traumatic brain injury and spinal cord injury; or
an immunological disease or disorder and the immunological disease or disorder is selected from the group consisting of lymphomas, leukemias, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic pupura (ITP), Evans Syndrome, vasculitis, bullous skin disorder, type I diabetes mellitus, Sjogren's syndrome, Delvic's disease, inflammatory myopathies, ankylosing spondylitis, and Crohn's disease; or
a cancer and the cancer is selected from the group consisting of renal cancer, breast cancer, lung cancer, prostate cancer, acute myelogenous leukemia (AML), papillary renal carcinoma, thyroid carcinoma, and low-grade glioma

### Claim at position 30

30-31. (canceled)

### Claim 32 (depends on 28)

The method of claim 28, wherein the disease or disorder is leprosy.

### Claim 33 (depends on 1)

A method of inhibiting LRRK2 in a subject comprising administering to the subject an amount effective to inhibit LRRK2 of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein LRRK2 is the G2019S mutant of LRRK2.

### Claim at position 34

35-38. (canceled)
